1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)

BACKGROUND: Nirsevimab is an extended half-life monoclonal antibody (mAb) newly authorized for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkins, Deidre, Hamrén, Ulrika Wählby, Chang, Yue, Domachowske, Joseph B, Englund, Janet A, Muller, William J, Leach, Amanda, Villafana, Tonya L, Kelly, Elizabeth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677985/
http://dx.doi.org/10.1093/ofid/ofad500.2465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677985/
http://dx.doi.org/10.1093/ofid/ofad500.2465

Ejemplares similares